Reagencie IVD Immulite - príl. II, zozn. A Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reagencie ivd immulite - príl. ii, zozn. a

siemens healthcare diagnostics inc. 511 benedict avenue 10591-5097 tarrytown, new york spojené štáty americké -

Reagencie IVD Immulite - príl. II, zozn. B Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reagencie ivd immulite - príl. ii, zozn. b

siemens healthcare diagnostics inc. 511 benedict avenue 10591-5097 tarrytown, new york spojené štáty americké -

Plášť operačný ster. Immunity Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

plášť operačný ster. immunity

batist medical productions s.r.o. (predtým batist) nerudova 744 549 41 Červený kostelec Česká republika -

Rukavice chirurgické sterilné Immunity Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rukavice chirurgické sterilné immunity

terang nusa sdn. bhd. no 2, jalan 8, pengkalan chepa 2, industrial zone 161 00 kota bharu, kelantan malajzia -

Strangvac Európska únia - slovenčina - EMA (European Medicines Agency)

strangvac

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - imunologické pomôcky pre koňovité - kone - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Saizen 5,83 mg/ml injekčný roztok v náplni Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

saizen 5,83 mg/ml injekčný roztok v náplni

merck serono s.p.a., taliansko - somatropín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Coxevac Európska únia - slovenčina - EMA (European Medicines Agency)

coxevac

ceva santé animale - inaktivovaná vakcína proti coxiella burnetii, kmeň nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Suvaxyn CSF Marker Európska únia - slovenčina - EMA (European Medicines Agency)

suvaxyn csf marker

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - ošípané - pre aktívnej imunizácie ošípaných od 7 týždňov veku a ďalej, aby sa zabránilo úmrtnosti a zníženie infekcie a ochorenia spôsobené classical swine fever virus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Mhyosphere PCV ID Európska únia - slovenčina - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - ošípané - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.